Drug Profile
Neumifil - Pneumagen
Alternative Names: NeumifilTMLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Pneumagen
- Class Anti-infectives; Antivirals; Proteins
- Mechanism of Action Epithelial cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Influenza virus infections
- Phase I Respiratory tract infections
- Preclinical COVID 2019 infections; Respiratory syncytial virus infections
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in United Kingdom (Intranasal, Spray)
- 02 Oct 2023 Efficacy and adverse events data from a phase II trial in Influenza virus infections released by Pneumagen
- 04 May 2023 Pneumagen completes a phase-II clinical trial in Influenza virus infections in United Kingdom (Intranasal) (NCT05507567)